[go: up one dir, main page]

DK3116511T3 - Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf - Google Patents

Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3116511T3
DK3116511T3 DK14885694.1T DK14885694T DK3116511T3 DK 3116511 T3 DK3116511 T3 DK 3116511T3 DK 14885694 T DK14885694 T DK 14885694T DK 3116511 T3 DK3116511 T3 DK 3116511T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
selenoorganic compounds
selenoorganic
compounds
Prior art date
Application number
DK14885694.1T
Other languages
English (en)
Inventor
Ronan Power
Zi-Jian Lan
Alexandros Yiannikouris
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Application granted granted Critical
Publication of DK3116511T3 publication Critical patent/DK3116511T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
DK14885694.1T 2014-03-14 2014-03-14 Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf DK3116511T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3116511T3 true DK3116511T3 (da) 2020-11-23

Family

ID=54072241

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14885694.1T DK3116511T3 (da) 2014-03-14 2014-03-14 Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK16187342.7T DK3144001T3 (da) 2014-03-14 2016-09-06 Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16187342.7T DK3144001T3 (da) 2014-03-14 2016-09-06 Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf

Country Status (16)

Country Link
US (3) US10201559B2 (da)
EP (1) EP3116511B1 (da)
JP (2) JP6313479B2 (da)
KR (3) KR102448455B1 (da)
CN (3) CN113694074A (da)
AU (4) AU2014386236B2 (da)
BR (1) BR112016020233B1 (da)
CA (1) CA2940283C (da)
DK (2) DK3116511T3 (da)
HU (2) HUE051713T2 (da)
IL (1) IL247312A0 (da)
MX (2) MX2016011897A (da)
PE (1) PE20211069A1 (da)
PT (1) PT3116511T (da)
RU (2) RU2665135C2 (da)
WO (2) WO2015137983A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665135C2 (ru) * 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20190076461A1 (en) * 2016-03-14 2019-03-14 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
US11014954B2 (en) 2017-05-19 2021-05-25 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
WO2020180814A1 (en) 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
WO2022020658A1 (en) * 2020-07-23 2022-01-27 Purdue Research Foundation Notch signaling inhibitors for treating obesity and metabolic disorders
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
JP2023076373A (ja) * 2021-11-22 2023-06-01 マルサンアイ株式会社 アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ－セクレターゼ産生抑制剤
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
US12285412B1 (en) 2024-12-27 2025-04-29 Imam Mohammad Ibn Saud Islamic University Organoselenium benzimidazole compounds for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
AU785355B2 (en) 1999-12-03 2007-02-01 Regents Of The University Of California At San Diego, The Phosphonate compounds
EP1268493B1 (en) 2000-03-31 2006-02-15 Purdue Research Foundation Phosphoramidate prodrugs
MXPA04010527A (es) 2002-04-26 2004-12-13 Gilead Sciences Inc Acumulacion celular de analogos de fosfonato de los compuestos inhibidores de la proteasa del virus de inmunodeficiencia humana (vih).
CA2485702C (en) 2002-05-13 2011-07-19 Metabasis Therapeutics, Inc. Novel phosphonic acid based prodrugs of pmea and its analogues
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20060093684A1 (en) 2004-10-28 2006-05-04 Iwao Takeda Seleniferous composition for producing antioxidase in vivo
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CA2598821C (en) * 2004-12-31 2011-05-31 Heonjoong Kang Organoselenium containing compounds and their use
US20060198906A1 (en) * 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US8865763B2 (en) * 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
WO2007127273A2 (en) 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
KR101503958B1 (ko) * 2007-08-31 2015-03-18 디에스엠 아이피 어셋츠 비.브이. 미용 및/또는 피부과학적 용도의 4-아미디노 벤질아민
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res USE OF HAPTOGLOBIN ENTYPIZATION FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
WO2011047434A1 (en) * 2009-10-22 2011-04-28 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
JP5895303B2 (ja) * 2011-04-01 2016-03-30 イアソマイ エービー Ｎ−アセチル−ｌ−システインを含む新規な組み合わせおよびその使用
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
SG11201507061XA (en) * 2013-03-15 2015-10-29 Alltech Inc Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
RU2665135C2 (ru) 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Also Published As

Publication number Publication date
US20160082033A1 (en) 2016-03-24
DK3144001T3 (da) 2021-11-15
CA2940283A1 (en) 2015-09-17
US9642874B2 (en) 2017-05-09
EP3116511A4 (en) 2017-10-18
EP3116511B1 (en) 2020-08-26
AU2014386236A1 (en) 2016-09-01
JP7009053B2 (ja) 2022-01-25
JP2017512828A (ja) 2017-05-25
PT3116511T (pt) 2020-11-19
AU2014386236B2 (en) 2019-07-11
MX2016011897A (es) 2017-04-27
AU2022204588A1 (en) 2022-07-21
JP6313479B2 (ja) 2018-04-18
RU2731383C2 (ru) 2020-09-02
CN106822168B (zh) 2020-11-27
KR20210104070A (ko) 2021-08-24
US10201558B2 (en) 2019-02-12
AU2019246818A1 (en) 2019-10-31
KR20160125989A (ko) 2016-11-01
RU2016136530A3 (da) 2019-11-25
BR112016020233A2 (da) 2017-08-15
JP2017078056A (ja) 2017-04-27
BR102016021058A2 (pt) 2017-05-30
AU2016222315B2 (en) 2022-08-04
EP3116511A1 (en) 2017-01-18
US10201559B2 (en) 2019-02-12
HUE056172T2 (hu) 2022-01-28
CN106456658A (zh) 2017-02-22
BR112016020233B1 (pt) 2022-07-19
AU2016222315A1 (en) 2017-03-30
US20160361338A1 (en) 2016-12-15
RU2665135C2 (ru) 2018-08-28
HUE051713T2 (hu) 2021-03-29
NZ723233A (en) 2020-10-30
MX2016011898A (es) 2018-03-12
RU2016136530A (ru) 2018-03-16
WO2015137983A1 (en) 2015-09-17
KR102764247B1 (ko) 2025-02-07
KR102466389B1 (ko) 2022-11-11
KR102448455B1 (ko) 2022-09-28
KR20170032862A (ko) 2017-03-23
WO2017048253A1 (en) 2017-03-23
AU2019246818B2 (en) 2021-02-25
CN113694074A (zh) 2021-11-26
CA2940283C (en) 2021-03-30
IL247312A0 (en) 2016-09-29
NZ723402A (en) 2024-11-29
PE20211069A1 (es) 2021-06-09
CN106822168A (zh) 2017-06-13
US20160045533A1 (en) 2016-02-18
RU2016133469A (ru) 2018-04-17

Similar Documents

Publication Publication Date Title
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese